Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Items 601–682 of 682
Paracrine regulation of glucagon secretion from pancreatic islets
Elliott, A. D. (2014)
Kohlenhydratstoffwechsel der Leber
de Heer, J. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0142-1
“Es ist seit langem bekannt, dass bei Patienten mit Diabetes mellitus Typ 2 (T2D) eine ausgeprägte Hyperglukagonämie vorliegt, die wesentlich zur gestörten Glukosetoleranz beiträgt [24].”
BackgroundBeneficial Effect of Naringin on Glucose Regulation in Type 1 Diabetic Mice
Jung, U. J., & Choi, M. (2015) · Journal of Agriculture & Life Science · doi:10.14397/jals.2015.49.3.133
LaPierre, M. P. (2015) · TSpace (University of Toronto)
The metabolic effects of leptin therapy and glucagon suppression therapy in mouse models of diabetes
Neumann, U. H. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0348695
“However, in the diabetic state characterized by a reduction in insulin producing β-cells, when insulin is injected subcutaneously, low levels of insulin reach the islet and hyperglucagonemia can persist [72, 73].”
BackgroundInfluentialCharacterization of b-cell Heterogeneity in the Islets of Langerhans
Bader, E. (2017) · mediaTUM (Technical University of Munich)
In vivo regulation of pancreatic beta cell function
van der Krieken, & Pieter, P. (2018) · Figshare
Long noncoding RNAs are critical regulators of pancreatic islet development and function
Singer, R. A. (2019) · doi:10.7916/d8-nnax-mb40
“While the majority of diabetes treatment options have focused on enhancing beta cell function to meet insulin demands, more recent work has shown that alpha cell dysfunction and hyperglucagonemia also contribute to disease pathophysiology (Unger and Cherrington, 2012; Brissova et al., 2018).”
BackgroundGlucagon Switches between GLP-1 and Glucagon Receptors in Normal and Hyperglycemic MicePreprint
Han, C., Zhang, Y., Zhu, W., Yang, G., Peng, X., Mehta, S., Zhang, J., Liu, Y., & Chen, L. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3273389
Mechanisms of Control of Type 2 Diabetes with Gastric Bypass
Landecho, M. F., Tuero, C., Valentí, V., Moncada, R., & Frühbeck, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-28803-7_41
Roger Harold Unger. L’homme par qui le glucagon a reçu ses lettres de noblesse
Vialettes, B. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.011
Coordinate control of metabolic flux with liver energy status by AMPK in vivo
Hasenour, C. M. (2014)
Sheryazdanova, D. N., Laryushina, Y., Muravlyova, L., Turgunova, L., Alina, A., Vassilyeva, N., & Turmukhambetova, A. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.4674
“Although the effects of GLP-1 are relatively preserved, prolonged hyperglycemia is capable of gradually suppressing the contrainsular response, creating a vicious cycle [30], [31].”
BackgroundTranscriptomic analysis of pancreatic islet cells derived from stem cells
Abrahamsen, M. (2020) · NVA (Nasjonalt vitenarkiv)
Robertson, L. T. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Gruber, B. L. M. (2021) · Mspace (University of Manitoba)
Heisler, L. K., & D’Agostino, G. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718163291.793490349
(2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835f8a71
Yu, R., Ren, S.-G., & Mirocha, J. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.11.002 · Cited by 3
Morel, C. M. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717978474.793471035
Biosynthesis, secretion, and action of glucagon
Lefèbvre, P. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch10 · Cited by 1
Friedman, J. M. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.06.002
Glucagon and Glucagon-Like Peptides
Kemp, D. M., & Habener, J. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.03825-3
FAM3D levels in women with gestational diabetes
Akşit, M., Akşit, M. Z., & Alan, Y. (2022) · Minerva Forensic Medicine · doi:10.23736/s2784-8922.22.01813-1
Advances in Islet Metabolomics using Hydrophilic Interaction Chromatography-Mass Spectrometry
Zegalia, K. A. (2022) · Deep Blue (University of Michigan) · doi:10.7302/6084 · Cited by 1
Future perspectives for diabetic retinopathy management
Li, W., & Zhang, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-93064-2.00006-8
Shigeto, H., Suzuki, Y., & YAMAMURA, S. (2023) · BUNSEKI KAGAKU · doi:10.2116/bunsekikagaku.72.233
Furió-Novejarque, C. (2024) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/202872
Role of insulin-degrading enzyme in pancreatic alpha-cell function.
Casanueva-Álvarez, E. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/66862
Ridout, S. A., Vellanki, P., & Nemenman, I. M. (2025) · eLife · doi:10.1101/2024.06.04.597343
“On the other hand, due to the much lower relative concentration of insulin produced in the islets by exogeneous insulin administration rather than endogenous insulin ( Unger and Cherrington, 2012 ), this seems unlikely.”
Guo, T., Zhang, H., Luo, Y., Yang, X., Wang, L., & Zhang, G. (2024) · Clinical and investigative medicine · doi:10.3138/cim-2024-2744
Ridout, S. A., Vellanki, P., & Nemenman, I. M. (2024) · eLife · doi:10.7554/elife.100193.1.sa0
Ridout, S. A., Vellanki, P., & Nemenman, I. M. (2024) · eLife · doi:10.7554/elife.100193.1
Wagner, R. J. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2384-6105
GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review
Furió-Novejarque, C., Díez, J.-L., & Bondía, J. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241285925 · Cited by 3
“50 However, the only models to include inhibition of glucagon secretion by GLP-1 in this selection are the proposals of Bosch et al 42 and Wu and An.”
Joko, S., Hashimoto, T., Yamashita, M., Tsuriya, D., Maekawa, M., & Iwaizumi, M. (2025) · Diabetology International · doi:10.1007/s13340-025-00797-y
“Glucose metabolism in pregnant women changes because of the placenta and the secretion of counterregulatory hormones [1].”
Ajao, F. O., Adeyeye, I. O., Kalejaiye, N. O., Mukaila, S. O., Agboola, O. S., & Iyedupe, M. O. (2025) · Annals of Clinical Gastroenterology and Hepatology · doi:10.29328/journal.acgh.1001050
Ridout, S. A., Vellanki, P., & Nemenman, I. M. (2025) · eLife · doi:10.7554/elife.100193.2 · Cited by 1
Ridout, S. A., Vellanki, P., & Nemenman, I. M. (2025) · eLife · doi:10.7554/elife.100193.3.sa3
Glucagon in Pediatric Metabolic Disorders: Pathophysiology and Therapeutic Perspectives
Pietro, G. M. D., Chiarelli, F., & Mohn, A. (2025) · Pediatric Reports · doi:10.3390/pediatric17050104
“In patients with hyperglycemia treated with insulin, glucagon excess contributes—at least in part—to poor glycemic control and may therefore be targeted through inhibition of glucagon secretion or action [45].”
Kontola, H., Crisóstomo, L., Löyttyniemi, E., Koskenniemi, J. J., Veijola, R., Toppari, J., & Kero, J. T. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf601
Loss of Slc39a5 in α-cells impairs glucose metabolism by chronically increasing glucagon
Chen, W. K., Cui, W., Xu, Y. J., Wang, X., Sun, X., Ren, J., Hou, N., Xiong, W., Xiao, R., & Zhang, X. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.013
“Previous study reported that glucagon receptor knockout mice prevented STZ induced hyperglycemia [10], indicating the central role of glucagon signaling in blood glucose regulation.”
Mitochondrial movement in pancreatic alpha cells requires Miro2 and is regulated by glucose
Ekstrand, M. H., Nawaz, S., Clark, A., Hastoy, B., & Knudsen, J. G. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110984 · Cited by 1
Inflammation und Blut-Hirn-Schranke
Heinemann, U., Milikovsky, D. Z., Veksler, R., & Schoknecht, K. (2015) · Clinical Epileptology · doi:10.1007/s10309-015-0010-9
Nelson, W. R. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.2537290
Zmazek, J. (2023) · University of Maribor digital library (University of Maribor)
Roles of Pharmacophores in Drug Discovery
Thai, K., Duong, C. Q., Tran, V.-T., & Nguyen, P. T. V. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_21
Specific Glucagon Assay System Using a Receptor-Derived Glucagon-Binding Peptide Probe
Shigeto, H., Suzuki, Y., & YAMAMURA, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010515
“The glucagon concentration [7,10] required for the diagnosis of diabetes is 20–50 pM; thus, the GBPs may need to improve in sensitivity for diagnostic applications in future.”
ZEMB, P. A., & Joulia, F. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6068352
Liu, T., Liang, R., Zhang, L., Ma, W., Xiangyu, W. A. N. G., Ren, H., & Wang, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.29.701913
“These observations reinforce the longstanding bihormonal hypothesis of diabetes pathogenesis, in which hyperglucagonemia emerges as one central driver of hyperglycemia rather than a mere byproduct of insulin deficiency 16,37,38 .”
Hu, Z., Zhu, M., Tang, L., Zhu, J., Yu, F., Huang, H., Yan, H., Xu, R., & He, H. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04028-0
“Preclinical evidence indicates that GCGR knockout mice are protected against diabetes induction following β-cell ablation [8].”
InfluentialGlucagon and Glucagon-Like Peptides
Kemp, D. M., & Habener, J. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00397-6
Insulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights
Häring, H., & Gallwitz, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00002-1
Boscolo, F. S., Mohan, S., LAURENTI, M. C., Kohlenberg, J. D., Christie, H. E., Egan, A. M., Vella, A. V., & Man, C. D. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00389.2025 · Cited by 1
Adaptive changes of human islets to an obesogenic environment in the mouse
Gargani, S. (2013) · theses.fr (ABES) · doi:10.70675/cebf7176z1bb8z414bzb159ze850f327d2d5
“Nowadays, part of scientific community declaims that decline of insulin secretion provokes some diabetes abnormalities and excess glucagon causes all the others (glucagocentric trend) [83].”
Evaluation pré-clinique et clinique de l'autogreffe intramusculaire d'îlots de Langerhans
Sterkers, A. (2013) · theses.fr (ABES) · doi:10.70675/d9118a8dz5ea5z4a92z8fd6z53090a4e6eee
“NNT : 2013LIL2S008. tel-00951952 Page 1 sur 88 THESE D’UNIVERSITE Evaluation pré‐clinique et clinique de l’autogreffe intramusculaire d’îlots de Langerhans PRESENTÉE ET SOUTENUE PUBLIQUEMENT PAR ADRIEN STERKERS SOUTENANCE LE 13 SEPTEMBRE 2013 DIRECTEUR DE THÈSE : PR FRANÇOIS PATTOU MEMBRES DU JURY : PRÉSIDENT : PR FRA…”
BackgroundInfluential村井, 謙. (2018) · Institutional Repositories DataBase (IRDB)
Lebreton, F. (2014) · theses.fr (ABES) · doi:10.70675/849757dbz779dz4590z8690zc0aee94ae5dc · Cited by 1
Role du neuropeptide 26RFa dans le controle de l'homéostasie glucidique par l'hypothlamus.
Mehdi, M. E. (2020) · theses.fr (ABES) · doi:10.70675/8b714030z33a9z4b08za1daz2e69dea9767b
A non-enzymatic function of neuraminidase 1 restrains hepatic glucagon response in mice
Sun, X.-M., Zhu, L.-Z., Wu, G.-D., Wang, T., Zhou, X.-Y., Liu, X.-H., Wang, Q., Jiang, W., Liu, B.-L., Pan, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72630-2 · Cited by 1
“Dysregulation of the hepatic glucagon response induces excessive hepatic glucose production, contributing to fasting hyperglycemia in diabetes 4,5 .”
Hasanova, K. G. (2024) · Azerbaijan Journal of Physiology · doi:10.59883/ajp.104
Nada, R. H., Mahdi, E. M., Abas, S. F. H., & Hameed, B. K. (2026) · Scientific Progress & Innovations · doi:10.31210/spi2026.29.01.33
“Pathophysiologically, this bihormonal imbalance contributes significantly to the dysregulation of hepatic glucose production, accelerating glycogenolysis and gluconeogenesis, which subsequently exacerbates chronic hyperglycemia [16].”
Liu, M., Davis, X. D., Ko, C., Shen, L., Fitzgerald, M., Lo, C. C., & Tso, P. (2026) · Cells · doi:10.3390/cells15131229
“While traditional diabetes management has remained overwhelmingly “insulin-centric,” glycemic homeostasis is fundamentally dictated by the delicate counter-regulatory balance between insulin and glucagon [4,26].”
InfluentialCurrent diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Glucagon: From Gene Regulation to Secretion
Koepke, J. P., dos Santos, T., MacDonald, P. E., & Light, P. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00002-0
Procopciuc, L. M., Hangan, A. C., & Lucaciu, R. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156622
“However, in insulin-resistant states, inappropriate glucagon secretion persists, increasing hepatic gluconeogenesis and hepatic glucose output [49].”
Peripheral GABA Signaling in Metabolic Adaptation and Maladaptation
Saliu, T. P., Adetunji, A. O., Ogunsile, J. O., Popoola, H. O., Ikele, C. M.-C., Miller, S. N., Oriakhi, K., Díaz, F., & Karaganis, S. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167141
“In type 2 diabetes mellitus (T2DM), inadequate insulin secretion and impaired insulin action are accompanied by insufficient restraint of glucagon activity, allowing α -cell output to contribute to inappropriate hepatic glucose production and persistent hyperglycemia [69,70].”
SGLT2 Inhibitors in Type 1 Diabetes: The Metabolic Perspective
Hamidi, V., & Mudaliar, S. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_825
Wu, S., Chen, Y., Zhang, J. X., & Zhang, J. (2026) · Journal of Cellular Physiology · doi:10.1002/jcp.70216 · Cited by 1
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
m6A mRNA methylation regulates pancreatic α-cell plasticity
Jesus, D. F. D., Brown, N. K., Fogarty, G., Gabriel, G., Wang, S., Wang, S., Shrestha, L., Kendall, K., Young, L., Hu, J., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01591-z
Reflections on the Brain’s Energy Crisis During Hypoglycemia
Schönfeld, P. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101016
“Consequently, glucose uptake by insulin-sensitive organs (liver, muscle, and white adipose tissue) is blocked, and in addition, the insulin-dependent inhibition of glycogenolysis and gluconeogenesis is removed [43].”
Irum Rehman, A. R. (2022) · Journal of Pharmaceutical Negative Results · doi:10.47750/d8f4e596
Characterization of endogenous D-amino acids in mammals via chiral separations
Lee, C. J. (2022) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Saldívar-Cerón, H. I., Maldonado-Trejo, D., Chavez-Castañeda, Q., Mercado-Guzmán, A. L., León-Barrita, A. D. J., López-García, I. A., Hernández-Solís, A., Ramírez-Mendoza, A. M., Terrazas-Delgado, D. A., Castañeda-Ramírez, A. E., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219654 · Cited by 1
Smith, C., Chen, T. Z., Skovso, S., Ching, J., Brownrigg, G. P., Kopp, J. L., & Rideout, E. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.27.762029
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.